Lone Star Bets $1B+ on Polymers with Radici-DOMO Double Deal

Lone Star Funds pulled off a rare same-day double acquisition on Wednesday, snapping up RadiciGroup's high-performance polymers and specialty chemicals divisions alongside the entirety of DOMO Engineered Materials — a move that consolidates two major European polyamide producers under single ownership for the first time.

The Dallas-based private equity giant didn't disclose deal values, but industry sources peg the combined transaction north of $1 billion based on the acquired businesses' footprint: 15 manufacturing sites spanning Italy, Germany, and China, plus roughly 3,000 employees and annual revenues estimated in the €800-900 million range. That's not accounting for the newly formed holding company's immediate synergy potential, which both Lone Star and the sellers flagged as central to the deal's rationale.

What makes this deal unusual isn't just the simultaneous close — it's the surgical precision. Lone Star isn't buying entire companies. It's carving out the high-margin, application-specific polymer units from two separate corporate parents and stitching them together into a new standalone platform. RadiciGroup keeps its synthetic fibers and nonwovens businesses. DOMO Chemicals retains its base chemicals and intermediates operations. What Lone Star gets is the engineering-grade stuff: polyamide 6 and 66 compounds used in automotive under-the-hood components, electrical connectors, and industrial machinery — markets where specs matter more than price and switching costs run high.

Angelo Radici, president of the Radici family holding company, framed the sale as a strategic refocus rather than a distress move. "This allows us to concentrate on our core textile and nonwovens activities while ensuring our polymers business joins a stronger platform," he said in the joint announcement. Translation: the polymers unit needed scale and capital that the family-controlled Italian conglomerate wasn't positioned to deliver.

Specialty polymers have been consolidating for years, but this deal accelerates a trend that's been quietly reshaping the industry since 2020. The global high-performance polyamide market — dominated by applications in automotive, electronics, and industrial equipment — has seen at least a dozen major M&A transactions in the past five years as producers chase scale, vertical integration, and access to sustainable feedstocks.

Lone Star's move mirrors BASF's 2023 acquisition of Solvay's polyamide business for €1.4 billion and Celanese's $1.6 billion purchase of DuPont's mobility and materials unit in 2022. The pattern is consistent: large producers buy out smaller, regionally focused players to consolidate customer relationships, eliminate redundant capacity, and gain leverage in raw material negotiations — particularly for adipic acid and caprolactam, the key building blocks for PA6 and PA66.

What differentiates this deal is the carve-out structure. Most recent polymers M&A has involved whole-company sales or division spin-offs from chemical majors. Here, Lone Star is buying specific business lines from two separate sellers and immediately merging them. That suggests the firm sees arbitrage potential: the combined entity should command better pricing power, rationalize overlapping product lines, and present a more attractive exit to a strategic buyer — likely within three to five years.

The timing also matters. European chemical producers have been under margin pressure since energy costs spiked in 2022, and while prices have since stabilized, the structural shift toward cheaper U.S. and Middle Eastern production hasn't reversed. Family-owned firms like RadiciGroup and DOMO lack the balance sheet firepower to retool plants for next-gen sustainable polymers — a gap that private equity, with patient capital and a clear exit timeline, is positioned to fill.

The new entity — which doesn't yet have a public name — will operate 15 production facilities and six R&D centers. The geographic split leans heavily European, with anchor plants in Novara, Italy (RadiciGroup's polymers HQ) and Leuna, Germany (DOMO's engineering materials base). Additional sites span Belgium, the Czech Republic, and China, the latter giving the platform a foothold in Asia's fast-growing automotive supply chain.

Annual production capacity is estimated at roughly 300,000 metric tons of polyamide compounds and resins, with revenue breakdown tilted toward automotive (approximately 55%), electrical and electronics (25%), and industrial applications (20%). That automotive exposure is both an asset and a risk. European auto production has been volatile — down 3% year-over-year in Q1 2026 — but the shift to electric vehicles is driving higher demand for lightweight, heat-resistant polymers in battery housings and electric motor components.

Lone Star's bet assumes that EV-driven polymer demand offsets any slowdown in traditional internal combustion engine production. That's plausible but not guaranteed. Chinese EV makers have been aggressively backward-integrating into materials, and if European automakers follow suit, third-party compounders could see pricing pressure.

The combined workforce of roughly 3,000 employees also poses integration risk. Lone Star has a track record of operational carve-outs — its 2018 acquisition and subsequent turnaround of Southwire's specialty wire business comes to mind — but merging two distinct corporate cultures, IT systems, and supply chains while maintaining customer relationships is a different level of complexity. The firm's statement emphasized "a commitment to operational excellence and sustainability," which in PE-speak usually means headcount optimization is on the table.

The table above reflects available public data and industry estimates. Lone Star has not disclosed audited financials for the acquired units, and both RadiciGroup and DOMO are privately held, so precise revenue and EBITDA figures remain opaque.

Strip away the press release language, and this deal is about three things: customer stickiness, margin resilience, and exit optionality. High-performance polyamides aren't commodities. Once an automotive Tier 1 supplier qualifies a resin for a specific component — say, a turbocharger housing or a sensor bracket — switching costs are prohibitive. That creates annuity-like revenue streams, especially in markets where regulatory compliance (think automotive safety standards) adds another layer of lock-in.

Both Lone Star and the sellers leaned hard on sustainability in the announcement. The combined platform "will be well-positioned to meet growing demand for sustainable, high-performance materials," the statement reads, citing investments in bio-based polyamides and recycled feedstocks.

That's directionally accurate but undersells the challenge. Bio-based PA6 and PA66 are still niche products — less than 5% of global polyamide production by most estimates — and the economics don't yet pencil at scale. Recycled polyamides face similar headwinds: collection infrastructure is patchy, and reprocessed resins often can't match virgin material performance in high-stress applications like automotive.

What's more likely is that Lone Star is positioning the platform for a future sale to a strategic buyer — think BASF, Covestro, or an Asian chemical major — that needs a sustainability story to tell investors and regulators. European chemical producers are under increasing pressure from the EU's Carbon Border Adjustment Mechanism and incoming Scope 3 emissions reporting requirements. A bolt-on acquisition of a platform already investing in green polymers looks better than building that capability from scratch.

So yes, sustainability is real. But it's also a value-creation lever — one that makes the exit more attractive.

The wildcard here is timing. If Lone Star can demonstrate 15-20% of revenue from sustainable sources by year three — plausible if they front-load capex into bio-based capacity — that could justify a premium multiple at exit. If not, the sustainability angle stays rhetorical.

Neither RadiciGroup nor DOMO disclosed whether this was an auction or a negotiated sale, but industry sources suggest at least two other financial sponsors — one U.S.-based, one European — ran diligence before walking. The most common sticking point in specialty chemicals carve-outs is stranded cost allocation: when you separate a business unit from its parent, you often inherit overhead, IT infrastructure, and shared services that don't scale efficiently on their own.

Lone Star evidently saw a path through that — likely because it's buying two units at once, creating immediate scale that offsets some of the stranded costs. The firm also has experience running complex industrial carve-outs through its portfolio, including its earlier ownership of Gentek building products and its ongoing investment in European industrial distribution platforms.

If you're tracking specialty chemicals M&A, this deal is a signal — not an outlier. Private equity's appetite for European industrials has been climbing since mid-2025, driven by valuation compression (European chemical stocks are trading at a 30% discount to U.S. peers) and the strategic logic of consolidation plays.

The Radici-DOMO transaction follows Apollo's acquisition of Clariant's pigments business in March 2026 and Advent International's take-private of Lanxess's specialty additives division in January. The common thread: sponsors are targeting mid-market chemical producers with defensible niches, high customer switching costs, and exposure to secular growth themes like lightweighting, electrification, and circular economy mandates.

The risk is that everyone's chasing the same playbook. As more capital floods into specialty chemicals roll-ups, entry multiples creep higher and exit windows narrow. Lone Star entered this deal at what appears to be a reasonable basis — likely 8-10x EBITDA for carved-out units, based on comparable transactions — but the exit environment three years out is harder to predict.

Strategic buyers have been selective, focusing on acquisitions that either add scale in core markets or unlock new geographies. A polyamide platform with strong European presence but limited North American or Asian reach might struggle to command a premium unless Lone Star invests in geographic expansion — which would require additional capital and extend the hold period.

Lone Star has three realistic exit paths, each with different risk profiles. A strategic sale to a chemical major — BASF, DuPont, Celanese, or an Asian player like Kingfa or Toray — is the cleanest outcome if the platform hits its growth targets. That buyer pool has capital, values synergies, and can stomach integration risk.

A secondary sale to another private equity fund is possible but less attractive unless the business meaningfully outperforms. PE-to-PE deals in specialty chemicals have been tough to price lately; buyers want proof of concept, not a turnaround thesis.

An IPO is the long-shot option. European chemicals IPOs have been sparse since 2021, and the public markets aren't rewarding cyclical industrials the way they did a decade ago. Unless the sustainability story is ironclad and growth is visible, listing this platform would likely mean leaving money on the table.

For all the strategic logic, this deal isn't without landmines. The first is execution. Carve-outs are messy. IT systems don't talk to each other. Supply agreements with the parent companies need to be renegotiated. Key employees leave. Lone Star's track record suggests it can navigate this, but the combined entity won't hit the ground running — year one will be about stabilization, not growth.

The second risk is customer concentration. If a significant portion of revenue comes from a handful of Tier 1 automotive suppliers — and those suppliers are themselves under margin pressure — pricing leverage erodes fast. The automotive supply chain is notoriously brutal on input costs, and polymers producers have limited ability to pass through raw material inflation when OEMs are squeezing every basis point.

The third risk is geopolitical. A European-heavy platform with exposure to Chinese manufacturing faces tariff uncertainty, supply chain fragmentation, and potential retaliation if U.S.-China trade tensions flare again. Lone Star will need to scenario-plan around regionalization — potentially adding North American capacity if customer demand justifies it.

None of these risks are disqualifying, but they're real. The difference between a solid return and a home run will come down to how well Lone Star executes in the first 18 months — and whether macro conditions (auto production, energy costs, trade policy) cooperate.

For the sellers, this is a classic portfolio rationalization. RadiciGroup, a family-controlled Italian conglomerate, has been in polymers since the 1960s but never scaled the business to the point where it could compete head-to-head with BASF or DuPont. The sale lets the family redeploy capital into synthetic fibers and nonwovens — markets where Radici has stronger competitive positioning and less need for continuous capex.

DOMO's calculus is similar. The Belgian chemical producer has been trimming non-core assets for years, refocusing on base chemicals and intermediates where it has integrated production and better margins. Selling the engineered materials unit removes a capital-intensive, customer-specific business that required constant R&D investment to stay competitive.

Neither seller disclosed proceeds, but both emphasized that the transactions allow them to strengthen their core franchises. That's corporate-speak for "we couldn't justify the investment required to grow these units, so we're selling to someone who can."

The interesting question is whether this triggers a broader wave of carve-outs among mid-tier European chemical producers. If Lone Star proves the model works — demonstrating that you can buy sub-scale specialty units, bolt them together, and exit at a premium — expect other sponsors to circle family-owned chemical companies with underinvested divisions.

Lone Star will need to name the combined entity and install a management team within the next 60-90 days. The CEO choice will signal intent: a polymers industry veteran suggests operational focus and a strategic exit; a private equity operating partner suggests aggressive cost restructuring and a secondary sale.

Customer retention metrics in Q3 and Q4 2026 will be the first real test. If key accounts stay sticky through the transition, the thesis holds. If major automotive or electronics customers start qualifying alternative suppliers, that's a red flag.

Beyond that, watch for follow-on M&A. If this platform works, Lone Star might bolt on additional specialty compounds businesses — particularly in North America or Asia — to create a truly global footprint. That would extend the hold period but also expand the exit buyer pool.

The broader market question is whether this deal marks a turning point for European chemicals M&A or just another data point in a sector that's been quietly consolidating for years. The answer probably depends on whether other sponsors can replicate the dual-carveout model — and whether strategic buyers are willing to pay up for scale in a market that's still, fundamentally, cyclical.